Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

First-in-Human Study of ABS-169 in Healthy Volunteers (PATH-169)

11 listopada 2026 zaktualizowane przez: Aerys Biosciences

A Phase I, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABS-169 in Healthy Volunteers

This is the first study of ABS-169 in people. ABS-169 is an oral investigational medicine that blocks MD2-TLR4 signalling, a pathway involved in inflammation and scarring (fibrosis) of organs such as the heart. The study will test single doses of ABS-169 or placebo in healthy adult volunteers to find out how safe and well tolerated it is, how much of the medicine gets into the blood and how quickly it is removed, and whether taking it with a high-fat meal changes how it is absorbed. Up to 40 healthy adults aged 18 to 55 will take part at one study centre in Melbourne, Australia.

Przegląd badań

Status

Jeszcze nie rekrutacja

Interwencja / Leczenie

Szczegółowy opis

ABS-169-001 is a single-site, randomised, double-blind, placebo-controlled, first-in-human study with 4 sequential single ascending dose (SAD) cohorts (25, 75, 150 and 200 mg, fasted) and one stand-alone food-effect cohort (25 mg, fed). Each cohort enrols 8 new participants randomised 6:2 to ABS-169 or matching placebo.

Each cohort starts with 2 sentinel participants (1 ABS-169, 1 placebo); the remaining 6 are dosed only after review of at least Day 2 safety data from the sentinels. Participants are screened from Day -28, admitted on Day -1, receive a single oral dose on Day 1, remain confined until Day 3, and return for an end-of-study visit on Day 7 (±1 day). Fasted cohorts fast for at least 10 hours before and 4 hours after dosing. In the food-effect cohort, participants eat a standard high-fat breakfast starting 30 minutes before dosing and finish it within 30 minutes.

Blood samples for ABS-169 and its metabolite dihydroartemisinin (DHA) are taken before dosing and at 5, 15 and 30 minutes and 1, 1.5, 2, 4, 8, 12 and 24 hours after dosing.

A Safety Review Committee reviews blinded safety data through Day 7 and blinded PK data to 24 hours before each dose escalation. Escalation requires evaluable data from at least 7 of 8 participants, including both sentinels. The projected mean exposure at the next dose must also stay within the exposure limit (Cmax 2,460 ng/mL; AUC 4,470 h·ng/mL), which is the exposure at the no-observed-adverse-effect level in the 28-day rat toxicology study. Intermediate or lower dose levels may be used, but the maximum dose will not exceed 200 mg without a protocol amendment.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

40

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

  • Nazwa: Nucleus Network recruitment team Recruiting Site
  • Numer telefonu: 1800 243 733

Lokalizacje studiów

    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Nucleus Network Pty Ltd
        • Kontakt:
          • Ofer Gonen
        • Główny śledczy:
          • Ofer Gonen, MBBS

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 55 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Written informed consent given before any study-related activities, with understanding of the nature, purpose, risks and adverse effects of the study.
  2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.
  3. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 at Screening.
  4. Medically healthy in the opinion of the PI or delegate, without clinically significant abnormalities, including: normal physical examination; systolic BP 90-140 mmHg and diastolic BP 40-90 mmHg; pulse rate 40-100 bpm; tympanic temperature 35.5-37.5°C; ECG without clinically significant abnormalities including QTcF <450 msec; respiration rate 10-22 breaths/min; SpO2 ≥95%; no clinically significant findings in clinical chemistry, haematology, coagulation and urinalysis.
  5. Female volunteers must agree not to donate ova until at least 35 days after dosing and must either be of non-childbearing potential (surgically sterilised at least 6 weeks before Screening, or postmenopausal with confirmatory FSH), or, if of childbearing potential, have negative pregnancy tests at Screening and Day -1, agree not to attempt pregnancy, and use adequate contraception (male partner condom plus a highly effective non-hormonal method) from one month before Screening until at least 35 days after dosing, unless exclusively in a same-sex relationship or abstinent as a committed lifestyle.
  6. Male volunteers must agree not to donate sperm until at least 95 days after dosing. With a female partner who could become pregnant, they must use a condom plus a highly effective method of contraception until at least 95 days after dosing. With a partner of non-childbearing potential or a same-sex partner, they must use a condom until at least 5 days after dosing.
  7. Suitable venous access for blood sampling.
  8. Willing and able to comply with all study assessments, schedule and restrictions.

Exclusion Criteria:

  1. Known hypersensitivity to the study drug or any of its ingredients.
  2. History of anaphylaxis or other significant allergy that would interfere with participation.
  3. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric or neurological disease, including any clinically relevant acute illness within the past 3 months.
  4. Major surgery or hospitalisation within 3 months before Screening, minor surgery under local anaesthetic within 1 month before Screening, or surgery planned during the study.
  5. Malignant disease in the last 10 years (except surgically resected skin squamous or basal cell carcinoma).
  6. Clinically relevant immunosuppression, including immunodeficiency conditions.
  7. Risk factors for torsade de pointes (including family history of long QT syndrome or sudden cardiac death) or a known arrhythmia.
  8. Gastrointestinal, liver (including Gilbert's syndrome), kidney or other conditions known to interfere with drug absorption, distribution, metabolism or excretion.
  9. History of known or unexplained bleeding disorders, or positive faecal occult blood test at Screening.
  10. GGT, bilirubin, ALP, AST or ALT >1.5× ULN. ALP/ALT/AST elevations may be accepted at PI discretion if they are normal variants without clinical signs.
  11. Estimated creatinine clearance <60 mL/min (Cockcroft-Gault) or serum creatinine >1.5× ULN.
  12. QTcF >450 msec (males) or >470 msec (females) confirmed on repeat; history of hypokalaemia or family history of long QT syndrome; or use of QT/QTc-prolonging medicines.
  13. Within 48 hours before dosing: caffeine or other xanthine-containing food or drink; foods that induce or inhibit liver enzymes (e.g., grapefruit, pomegranate, mango, dragon fruit); alcohol; or other factors affecting drug ADME, such as strenuous exercise.
  14. History of, or positive Screening test for, HIV, hepatitis B surface antigen or hepatitis C antibodies.
  15. Positive drugs-of-abuse or alcohol breath test at Screening or Day -1 (positive cotinine at Screening is not exclusionary).
  16. Regular consumption of more than 10 standard drinks per week or more than 4 standard drinks on any one day.
  17. Smoking more than 5 cigarettes (or equivalent nicotine products) per week, or unwilling to abstain from 72 hours before Day -1 and throughout confinement.
  18. Females who are breastfeeding or plan to breastfeed from Screening until 3 months after dosing.
  19. Unable to swallow oral medication.
  20. Use of any prescription or over-the-counter medication, including herbal products, vitamins and hormone supplements, within 7 days or 5 half-lives (whichever is longer) before dosing. Exceptions: contraceptives, paracetamol up to 2 g/day and ibuprofen up to 1.2 g/day, each for no more than 3 consecutive days. Drugs with known risk of TdP are prohibited.
  21. Current infection requiring systemic antibiotic, antifungal, antiparasitic or antiviral medication within 10 days before dosing.
  22. Any vaccination within 30 days before Screening.
  23. Blood or plasma donation, or blood loss >500 mL, within 30 days before dosing, or blood transfusion within 1 year.
  24. Participation in a study of an investigational drug or device within 30 days or 5 half-lives (whichever is longer) before Screening.
  25. Any other condition or prior therapy that, in the PI's opinion, makes the volunteer unsuitable, including likely non-compliance.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Cohort A1: ABS-169 25 mg (fasted)

Single oral dose of ABS-169 25 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Eksperymentalny: Cohort A2: ABS-169 75 mg (fasted)

Single oral dose of ABS-169 75 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Eksperymentalny: Cohort A2 (FE): ABS-169 25 mg (fed)

Single oral dose of ABS-169 25 mg on Day 1 after a standard high-fat breakfast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Eksperymentalny: Cohort A3: ABS-169 150 mg (fasted)

Single oral dose of ABS-169 150 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Eksperymentalny: Cohort A4: ABS-169 200 mg (fasted)

Single oral dose of ABS-169 200 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Komparator placebo: Placebo (pooled across cohorts)

Single oral dose of matching placebo on Day 1, fasted or fed according to cohort (n=2 per cohort, up to 10)

Matching oral capsule containing microcrystalline cellulose, single dose

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of participants with treatment-emergent adverse events (TEAEs)
Ramy czasowe: Day 1 (dosing) through Day 7 (plus or minus 1 day)

TEAEs, including serious AEs, by severity and relationship to study drug (MedDRA). AEs are recorded from signing of consent; TEAEs are those starting or worsening after dosing.

Day 1 (dosing) through Day 7 (plus or minus 1 day)
Number of participants with clinically significant abnormalities in vital signs, 12-lead ECGs, clinical laboratory tests or physical examination
Ramy czasowe: Baseline (Screening and Day -1) through Day 7 (plus or minus 1 day)

Vital signs: blood pressure, pulse rate, respiratory rate, temperature, SpO2. ECG: including QTcF. Laboratory: haematology, chemistry, coagulation, urinalysis. Clinical significance is judged by the investigator.

Baseline (Screening and Day -1) through Day 7 (plus or minus 1 day)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Maximum Observed Plasma Concentration (Cmax) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

Cmax of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

Tmax of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

AUClast of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

AUCinf of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Terminal Elimination Half-life (t1/2) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

t1/2 of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Apparent Oral Clearance (CL/F) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

CL/F of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Apparent Volume of Distribution During the Terminal Phase (Vz/F) of ABS-169
Ramy czasowe: Pre-dose through 24 hours post-dose

Vz/F of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Dose Proportionality of ABS-169 Cmax
Ramy czasowe: Pre-dose through 24 hours post-dose

Slope estimate with 90% confidence interval from a power model of log-transformed Cmax versus log-transformed dose across 25 to 200 mg (fasted cohorts).

Pre-dose through 24 hours post-dose
Dose Proportionality of ABS-169 AUCinf
Ramy czasowe: Pre-dose through 24 hours post-dose

Slope estimate with 90% confidence interval from a power model of log-transformed AUCinf versus log-transformed dose across 25 to 200 mg (fasted cohorts).

Pre-dose through 24 hours post-dose
Effect of Food on ABS-169 Cmax
Ramy czasowe: Pre-dose through 24 hours post-dose

Geometric mean ratio (fed/fasted) with 90% confidence interval for Cmax, comparing 25 mg fed (Cohort A2-FE) with 25 mg fasted (Cohort A1), from a general linear model on log-transformed data.

Pre-dose through 24 hours post-dose
Effect of Food on ABS-169 AUCinf
Ramy czasowe: Pre-dose through 24 hours post-dose

Geometric mean ratio (fed/fasted) with 90% confidence interval for AUCinf, comparing 25 mg fed (Cohort A2-FE) with 25 mg fasted (Cohort A1), from a general linear model on log-transformed data.

Pre-dose through 24 hours post-dose

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Identification of ABS-169 Metabolites in Plasma
Ramy czasowe: Pre-dose through 24 hours post-dose

Qualitative identification of ABS-169 and its metabolite if significant.

Pre-dose through 24 hours post-dose

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Ofer Gonen, MBBS, Nucleus Network Pty Ltd.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 listopada 2026

Zakończenie podstawowe (Szacowany)

1 sierpnia 2027

Ukończenie studiów (Szacowany)

1 stycznia 2028

Daty rejestracji na studia

Pierwszy przesłany

22 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 listopada 2026

Pierwszy wysłany (Rzeczywisty)

17 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • ABS-169-001
  • 2026-09-1741 (Inny identyfikator: Bellberry Limited Human Research Ethics Committee (Bellberry Application No.))

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

"There is no plan to make individual participant data available. Summary results will be posted on ClinicalTrials.gov."

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj